FDA Approves METFORMIN HYDROCHLORIDE — Zydus Lifesciences Limited

Zydus Lifesciences Limited announced the FDA approval of generic metformin hydrochloride tablets (ANDA 203686), a strategic move that is expected to bolster their U.S. portfolio and intensify competition in the generic oral anti-diabetic market. This authorization allows the company to offer an accessible alternative to existing brand-name therapies, creating a projected opportunity for significant revenue growth amidst general industry softness.